Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D known ✓ | P25100 | 20/20 | 0.63 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.56 |
| ▸ | ADRA1B known ✓ | P35368 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13541137 | 0.99 | ADRA1D (0.65) | ADRA1DADRA1AADRA1B | |
| SCHEMBL3487419 | 0.90 | ADRA1D (0.66) | ADRA1DADRA1AADRA1B | |
| Hydrochloric Acid SCHEMBL3488253 | 0.89 | ADRA1D (0.65) | ADRA1DADRA1AADRA1B | |
| SCHEMBL13542663 | 0.88 | ADRA1D (0.63) | ADRA1DADRA1AADRA1B | |
| Bromide SCHEMBL3488896 | 0.87 | ADRA1D (0.62) | ADRA1DADRA1AADRA1B | |
| SCHEMBL13541138 | 0.86 | ADRA1D (0.63) | ADRA1DADRA1AADRA1B | |
| SCHEMBL13542538 | 0.86 | ADRA1D (0.63) | ADRA1DADRA1AADRA1B | |
| SCHEMBL3488605 | 0.85 | ADRA1D (0.65) | ADRA1DADRA1AADRA1B | |
| Trifluoroacetic Acid SCHEMBL3487921 | 0.84 | ADRA1D (0.59) | ADRA1DADRA1AADRA1B | |
| SCHEMBL13541135 | 0.84 | ADRA1D (0.67) | ADRA1DADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8470859-B2 | Iminopyridine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-06-25 | — | — | US | disclosed |
| EP-2535330-A2 | Iminopyridine derivative and use thereof | Takeda Pharmaceutical Company Limited (JP) | 2012-12-19 | — | — | EP | disclosed |
| US-20100016315-A1 | Iminopyridine Derivative and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-2077262-A1 | IMINOPYRIDINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2009-07-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016315-A1 | Iminopyridine Derivative and Use Thereof | ADRA1D, ADRB1, ADRB2 | ADRA1D 1/4885ADRA1A 4/4885ADRA1B 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.